SUO 2019: The SUO-CTC Phase III Adstiladrin® Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer

SUO 2019 Bladder Cancer Phase III Adsiladrin Trial for BCG Unresponsive non-muscle invasive bladder cancer, Colin Dinney, high dose Adstiladrin® in patients with high-grade NMIBC who are unlikely to benefit from further intravesical BCG.

Read the full article here

Related Articles